Immodulon Therapeutics is focused on developing innovative cancer immunotherapy solutions, particularly through its lead product, IMM-101. This agent is a heat-killed strain of Mycobacterium obuense, designed to act as a broad-spectrum immunomodulator. The primary goal of IMM-101 is to prime and enhance the innate immune response in patients, thereby improving the effectiveness of various cancer treatments, including chemotherapy and checkpoint inhibitors. This approach is particularly significant for treating "cold" tumors, such as pancreatic cancer, which typically exhibit a weak immune response.

The company is in the late stages of clinical development and has recently formed a Scientific Advisory Board (SAB) composed of leading experts in oncology to support the advancement of IMM-101 into pivotal trials. This board, chaired by Professor Dr. med. Thomas Seufferlein, aims to leverage the extensive experience of its members to guide the clinical development process. Immodulon is committed to addressing the challenges faced by patients with difficult-to-treat cancers, and the formation of the SAB underscores its dedication to enhancing the therapeutic potential of its immunotherapy approach.

United Kingdom

Immodulon Therapeutics Limited is a private, clinical-stage, immuno-oncology company dedicated to the development of novel, safe and effective treatments for cancer patients.

Immodulon Therapeutics

Company Details